Key facts
- This page summarizes Frank J. Williams's Form 4 filing for Evolent Health, Inc. (EVH).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Jun 2023, 16:23.
Frank J. Williams - 01 Jun 2023 Form 4 Insider Report for Evolent Health, Inc. (EVH)
- Reporting relationship
- Director
- Issuer ticker
- EVH
- Reported as of
- 01 Jun 2023
- Net transaction value
- -$2,182,212
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2023, 16:23:51 UTC
- Prior SEC filing
- 03 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Weinberg, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Frank J. Williams filed Form 4 for Evolent Health, Inc. (EVH) on 05 Jun 2023.
Change
- Previous filing in this sequence was filed on 03 May 2023.
- Current net transaction value: -$2,182,212.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVH
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $130,942
- Shares
- +19,060
- Change %
- +2.3%
- Price
- $6.87*
- Shares after
- 838,872
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
EVH
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $933,954
- Shares
- +90,940
- Change %
- +11%
- Price
- $10.27
- Shares after
- 929,812
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
EVH
transaction
Class A Common Stock
Sale
- Transaction value
- $266,094
- Shares
- -9,091
- Change %
- -0.98%
- Price
- $29.27
- Shares after
- 920,721
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
EVH
transaction
Class A Common Stock
Sale
- Transaction value
- $296,578
- Shares
- -9,969
- Change %
- -1.1%
- Price
- $29.75
- Shares after
- 910,752
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F4
EVH
transaction
Class A Common Stock
Sale
- Transaction value
- $1,226,404
- Shares
- -41,914
- Change %
- -4.6%
- Price
- $29.26
- Shares after
- 868,838
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F5
EVH
transaction
Class A Common Stock
Sale
- Transaction value
- $1,458,033
- Shares
- -49,026
- Change %
- -5.6%
- Price
- $29.74
- Shares after
- 819,812
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F6
EVH
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 66,064
- Date
- 01 Jun 2023
- Ownership
- See footnote
- Footnotes
- F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVH
transaction
Derivative
Class A Common Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -19,060
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jun 2023
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 19,060
- Exercise price
- $6.87
- Footnotes
- F1, F8
EVH
transaction
Derivative
Class A Common Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -90,940
- Change %
- -84%
- Price
- $0.000000
- Shares after
- 17,250
- Date
- 01 Jun 2023
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 90,940
- Exercise price
- $10.27
- Footnotes
- F1, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 9 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.
Footnote F2
Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.63 to $29.62, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.83, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.60 to $29.59, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $29.86, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F7
Shares held of record by the Frank Williams Irrevocable Trust. Mr. Williams serves as the Trustee of the Frank Williams Irrevocable Trust.
Footnote F8
The Class A Common Stock Options exercised vested on February 1, 2019.
Footnote F9
The Class A Common Stock Options exercised vested on March 1, 2017, March 1, 2018, March 1, 2019, and March 1, 2020.